Physician profile
Nadeem Raza
NPI 1861411522
$2,550.06
in general payments reported to CMS, 2019-2025
13 companies · $883 in 2025
The $883 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $250 · 2021: $321 · 2022: $390 · 2023: $304 · 2024: $403 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $741.72 | 2021-2025 | |
| Glaxosmithkline, LLC. | $623.58 | 2020-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $303.95 | 2022-2025 | Airsupra |
| Actelion Pharmaceuticals US, INC. | $246.90 | 2024-2025 | Opsumit, Uptravi |
| Amgen INC. | $124.99 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.98 | 2021 | |
| Phathom Pharmaceuticals, INC. | $124.73 | 2025 | Voquezna |
| Novo Nordisk INC | $121.82 | 2025 | Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $51.18 | 2022 | |
| Exact Sciences Corporation | $25.01 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $25.00 | 2025 | Vaxneuvance, Gardasil 9 |
| Alk-Abello, INC | $18.27 | 2025 | Neffy |
| Agios Pharmaceuticals, INC. | $17.93 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.